Canabidiol Na Qualidade De Vida Em Pacientes Com Demências: Desafios E Perspectivas No Contexto Brasileiro

Abstract

Dementia-related diseases represent a growing public health issue due to population aging and the lack of therapies capable of significantly halting or slowing neurodegeneration. Cognitive decline and associated behavioral symptoms, such as agitation and anxiety, make managing these conditions challenging for both patients and caregivers. In this context, cannabidiol (CBD), a non-psychoactive compound from Cannabis sativa, has recently emerged as a potential therapeutic option for the treatment of dementias due to its possible neuroprotective, anti-inflammatory, and antioxidant properties, as well as its benefits in controlling behavioral symptoms. This integrative review on the use of CBD in dementia treatment explores its effects on the biological mechanisms underlying neurodegeneration, including the reduction of neuroinflammation and oxidative stress, as well as its impact on the modulation of the endocannabinoid system. The results suggest that CBD may be effective in controlling behavioral symptoms, such as agitation and sleep disturbances, commonly observed in dementia patients, and may potentially slow the progression of neurodegeneration. However, despite promising findings from preclinical studies and early clinical trials, scientific evidence remains limited, indicating the need for larger-scale studies to elucidate its efficacy. Additionally, regulatory barriers restrict the use of CBD in Brazil, raising costs and limiting patient access to treatment and further scientific development. In conclusion, while cannabidiol (CBD) shows promising potential in treating dementias, both for neuroprotection and behavioral symptom management, further research and law adjustments are still required. A stronger scientific foundation and a favorable regulatory environment could consolidate CBD as an important therapeutic option for dementia patients in Brazil.